KMDA Kamada Ltd.

NASDAQ
$7.74

Kamada Ltd. (KMDA) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on November 9, 2026.

Kamada Beat Consensus Estimates, Raises Guidance
Monday, November 9, 2026 · 7:02 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 7:05 AM ET
Earnings Whisper
-
vs $0.12
Rev est $51.51M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $8.00

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kamada Ltd.

Kamada Ltd is an orphan drug, plasma-derived protein therapeutics company and develops and produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.